NICE recommends Celgene’s Ozanimod to treat ulcerative colitis
pharmaphorum
SEPTEMBER 7, 2022
The recommended initial dosage is low, with a gradual build up in dosage, so as to reduce possible side effects such as upper respiratory infection, urinary tract infection, and hypertension. Clinical trial results showed a significant reduction in symptoms when people took ozanimod, as compared with a placebo.
Let's personalize your content